BMS recalls blood-pressure drug Avalide; Sun gets tentative OK for Crestor copy;

 @FiercePharma: Chief Justice unloads Pfizer shares. Article | Follow @FiercePharma

From the archives: Top 10 Pharma CEO salaries of 2009. Report

> Bristol-Myers Squibb is recalling 60 million tablets of the blood pressure medication Avalide in the U.S. and Puerto Rico. Report

> Sun Pharmaceutical Industries won tentative marketing approval for a generic version of AstraZeneca's cholesterol drug Crestor. Report

> Novartis lost a U.K. appeal to overturn a ruling that invalidated its European patent for extended-wear contact lenses in a lawsuit against Johnson & Johnson. Report

> A Maryland couple has filed a wrongful death lawsuit against Pfizer, saying that a switch in formulation for its Dilantin epilepsy drug caused their son's death. Report

> GlaxoSmithKline has tapped soccer star Mia Hamm for its public health campaign to emphasize the need for adults to make vaccinations part of their overall health-and-wellness goals. Report

> Regulators approved the wider use of GlaxoSmithKline's clot-busting medicine Arixtra (fondaparinux) throughout the European Union. Report

> Marketing rights for cancer treatment Caeylx outside the U.S. will be returned to Janssen from Merck after a licensing deal expires in December. Report

> Warner Chilcott has completed the sale of $500 million in debt to finance its acquisition of the U.S. rights to the bladder treatment Enablex. Report

> AstraZeneca Pharma India said its public shareholders did not approve a special resolution to delist the company from the stock exchanges, leading its shares to fall more than 3 percent. Report

Biotech News

 @FierceBiotech: Lilly research chief outlines the perfect biotech pact. Article | Follow @FierceBiotech

 @JohnCFierce: Genzyme's Termeer says he's ready to go, when the price and time is right. But don't look for a snap deal with Sanofi. Report |  Follow @JohnCFierce

> HIV vax researchers ponder best R&D strategies in Atlanta. Article

> Protox lines up $35M for BPH program. Story

> Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial. Report

> Sanofi pipeline review overshadowed by Genzyme maneuvers. Item

Vaccines News

> Withdrawn Sanofi Hep B vax continues to help kids. Story

> HIV vaccine researchers ponder new strategies, drop in funding. Article

> HHS chief promises cell-based flu vax in 2011. News

> Vax experts discuss trials, tribulations of malaria R&D. Report

Manufacturing News 

> Xcelience boosts solid oral dosage form capabilities. News

> Lannett and Cody pass FDA muster. Story

> Service calculates API-making costs for generics. News

> India finds execs liable for manufacturing defects. Report

And Finally... A nationwide shortage of several widely used anesthetics, which has been exasperating doctors and veterinarians for months, has now spread to the country's death rows. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.